Addendum

Dupilumab (atopic dermatitis in adolescents) - Addendum to Commission A19-75

Report documents

Indication:

Adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy

Result of dossier assessment:

Now hint (before: indication) of non-quantifiable added benefit

2020-02-20 A G-BA decision was published.

Project no.: A20-01
Commission: Commission awarded on 06.01.2020 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Skin and hair
Note: If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.